Brief: Amneal Receives U.S. FDA Approval For Risperidone Extended-Release Injectable Suspension
04/09/2025 22:28
Amneal Pharmaceuticals Inc AMRX.O: AMNEAL RECEIVES U.S. FDA APPROVAL FOR RISPERIDONE EXTENDED-RELEASE INJECTABLE SUSPENSION AMNEAL PHARMACEUTICALS INC - PRODUCT LAUNCH PLANNED FOR Q4 2025 Source text: ID:nGNX8gPffF Further company coverage: AMRX.O
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study